A Study of GSM-779690T in Healthy Adult Participants
Starting soon · Phase 1 · Has a placebo group
Conditions studied: Healthy Adult Participants, Alzheimer Disease
In brief
A Phase 1, single-centre, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a single and multiple dose regimens of GSM-779690T in healthy adults. This first-in-human study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GSM-779690T.
Key facts
- Study ID
- NCT07690228
- Run by
- Acta Pharmaceuticals
- People needed
- 72
- Starts
- 2026-08-15
- Expected to finish
- 2027-07-15
- Last updated by the study team
- 2026-07-09
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.
Where it is running
- Nucleus Network Pty Ltd — Melbourne, Victoria, Australia
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.